

# MB-CART19.1 in Refractory SLE

NCT06189157

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 1, Phase 2
<b>Sponsor</b>	Miltenyi Biomedicine GmbH
<b>Enrollment</b>	29 participants

## Key Eligibility Criteria

---

### Inclusion (17)

- Patients at least 18 years of age.
- Signed and dated informed consent before the conduct of any trial-specific procedure.
- SLE fulfilling the 2019 ACR/EULAR classification criteria (refer to Appendix 8).
- One BILAG A or two BILAG B despite treatment with at least two of the following treatment options: MMF, cyclophosphamide, rituximab belimumab, anifrolumab, methotrexate, azathioprine.
- SLE with major organ involvement defined as either:  
... and 12 more (see full listing online)

### Exclusion (32)

- Active clinically significant central nervous system (CNS) dysfunction (including but not limited to uncontrolled seizure disorders, cerebrovascular ischemia or hemorrhage, dementia, paralysis).
- Uncontrolled diabetes mellitus.
- Therapy induced lung disease and tuberculosis.
- Forced Vital Capacity (FVC)  $\leq$  60 %, FEV1  $\leq$  60 %, Total Lung Capacity (TLC)  $\leq$  60 % and DLCO (diffusion capacity)  $\leq$  60 %.
- BILAG A or BILAG B for neuropsychiatric SLE.  
... and 27 more (see full listing online)

## Locations (3 total)

---

Universitätsklinikum Erlangen, Medizinische Klinik 3, Erlangen, Germany  
Otto-von-Guericke-Universität Magdeburg, Magdeburg, Germany  
Universitätsklinikum Tübingen - Medizinische Universitätsklinik Abt. II, Tübingen, Germany